International Journal of Research and Review Vol.7; Issue: 11; November 2020 Website: www.ijrrjournal.com Review Article E-ISSN: 2349-9788; P-ISSN: 2454-2237 International Journal of Research and Review (ijrrjournal.com) 484 Vol.7; Issue: 11; November 2020 A Review on Anti Obesity Drugs Jose Mathew, Krishnaveni Kandasamy, Shanmugasundaram Rajagopal, Sambathkumar R Department of Pharmacy Practice, J.K.K Nattraja College of Pharmacy, Komarapalayam-638183, Tamil Nadu, India Corresponding Author: Krishnaveni Kandasamy ABSTRACT Obesity is a potentially life-threatening, chronic disease. As the most prevalent metabolic disorder affecting humans today, obesity requires multidisciplinary, long-term treatment. The worldwide prevalence of obesity has experienced a remarkably steady increase. Yet treatment is essential because obesity has been linked to the onset of many other chronic diseases, as well as higher rates of comorbidities and mortality. Weight loss of 5% to 10% of initial weight, accomplished by intense lifestyle treatment, decreases risk factors for cardiovascular disease (CVD), avoids or delays the progression of type 2 diabetes, and enhances other health effects of obesity. There is a need for adjunctive treatments that can help patients with dietary changes alone that are unable to lose or sustain adequate weight loss to improve health. With newly developed clinical guidelines, a better understanding of the biology of energy balance and patient variability in treatment response, and an increased availability of several monotherapy and combination anti- obesity medicines, we will start to better research and customize individualized treatments for the many different types of obesity. Keywords: Obesity, Noradrenergic Activation, Gastrointestinal Lipase Inhibition, Serotonin Receptor Activation, Combination Therapy INTRODUCTION Obesity is a potentially life- threatening, chronic disease. As the most prevalent metabolic disorder affecting humans today, obesity requires multidisciplinary, long-term treatment 1,2 . The worldwide prevalence of obesity has experienced a remarkably steady increase. Yet treatment is essential because obesity has been linked to the onset of many other chronic diseases, as well as higher rates of comorbidities and mortality 3-5 . Despite the lack of significant long-term effectiveness, lifestyle change remains the cornerstone of obesity treatment. Pharmacotherapy is a viable treatment choice for many who don't respond to lifestyle therapy and are not candidates for weight loss surgery. Advances in understanding the processes of appetite control, nutrient sensing, and energy expenditure have not only helped shape the current drug growth, but also changed the way anti-obesity drugs are provided. 6 Obesity is a complex, highly regulated disease, with more than 150 related co morbidities, including diabetes, cardiovascular disease, non-alcoholic fatty liver disease and many types of cancer. Although many people can lose weight in the short term with lifestyle modification, few maintain their weight loss. 7 On the basis of our past understanding of obesity, drug therapy was directed either at appetite suppression or impairment of nutrient absorption, with the goal of reducing caloric intake and thus body weight. The findings were less than expected and the emergence of major adverse effects not only strengthened the idea that obesity was a voluntary or behavioural problem. Weight loss of 5% to 10% of initial weight, accomplished by intense lifestyle treatment, decreases risk factors for cardiovascular disease (CVD), avoids or delays the progression of type 2 diabetes,